Vicore Pharma: Additional Update on IPF Program in Q4 - Redeye

Redeye is positive to the indication of continued strong performance in the ongoing phase II “AIR” trial in IPF, in line with the interim readout from February according to today's release, which would be major news if replicated and presented in a larger patient population (ie, a sizable interim readout or full study). Vicore guides today that a second interim analysis is planned for Q4, where the company also expects to present the remaining development program in IPF. We will await further data points before we draw any additional conclusions, but we look forward to an eventful H2.

Länk till analysen i sin helhet: https://www.redeye.se/research/854656/vicore-pharma-additional-update-on-ipf-program-in-q4?utm_source=finwire&utm_medium=RSS